| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Oct―17 |
Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome |
M.M. Said, A.M. Braam, E. Duijvelaar, J.R. Schippers, L. Atmowihardjo, J. Twisk, et al. (+4) H.J. Bogaard, E.L. Swart, J. Aman, I.H. Bartelink |
| 2 |
[GO] |
2025―Oct―07 |
SARS-CoV-2 N7-Methyltransferase Inhibitors: Towards Selective and Potent Antivirals |
Katarina Sujova, Vladimir Frecer |
| 3 |
[GO] |
2025―Jan―16 |
The impact of community pharmacies on equity in access to professional rapid antigen testing for SARS-CoV-2 in Portugal |
José Guerreiro, Sónia Romano, Inês Teixeira, Klára Dimitrovová, Rúben Pereira, António Teixeira Rodrigues, Ema Paulino |
| 4 |
[GO] |
2024―Mar―11 |
Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs. |
Lea-Adriana Barlang, Isabelle Deimel, Björn-Patrick Mohl, Claudia Blaurock, Anne Balkema-Buschmann, Kristina Weinbender, et al. (+4) Brian Hess, Helena Obernolte, Olivia M. Merkel, Andreas Popp |
| 5 |
[GO] |
2023―Dec―14 |
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 |
Fabiola Guareschi, Elena Del Favero, Caterina Ricci, Laura Canté, Martina Brandolini, Vittorio Sambri, et al. (+7) Sara Nicoli, Silvia Pescina, Davide D'Angelo, Irene Rossi, Francesca Buttini, Ruggero Bettini, Fabio Sonvico |
| 6 |
[GO] |
2023―Sep―30 |
A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects |
Xin-Mei Yang, Yang Yang, Bu-Fan Yao, Pan-Pan Ye, Yan Xu, Shao-Ping Peng, et al. (+23) Yu-Mei Yang, Pan Shu, Pei-Jin Li, Shan Li, Hong-Lin Hu, Qian Li, Lin-Lin Song, Ke-Guang Chen, Hai-Yan Zhou, Ye-Hui Zhang, Fu-Rong Zhao, Bo-Hao Tang, Wei Zhang, Xin-Fang Zhang, Shu-Meng Fu, Guo-Xiang Hao, Yi Zheng, Jing-Shan Shen, Ye-Chun Xu, Xiang-Rui Jiang, Lei-Ke Zhang, Ren-Hong Tang, Wei Zhao |
| 7 |
[GO] |
2023―Jul―23 |
Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection |
Yuchen Qu, Cunjin Su, Zheng Xiang, Yueyuan Wang, Junping Han, Jie Pan, Zhu Shen |
| 8 |
[GO] |
2023―Jun―11 |
AEROSOLIZED SULFATED HYALURONAN DERIVATIVES PROLONG THE SURVIVAL OF K18 ACE2 MICE INFECTED WITH A LETHAL DOSE OF SARS-COV-2 |
Mauro Pavan, Chiara D. Fanti, Alba Di Lucia, Elena Canato, Laura Acquasaliente, Fabio Sonvico, et al. (+11) Jennifer Delgado, Amberlee Hicks, Jordi B. Torrelles, Viraj Kulkarni, Varun Dwivedi, Anna M. Zanellato, Devis Galesso, Gianfranco Pasut, Francesca Buttini, Luis Martinez-Sobrido, Cristian Guarise |
| 9 |
[GO] |
2023―Mar―02 |
Pharmacokinetics and Pharmacodynamics of Imatinib for Optimal Drug Repurposing from Cancer to COVID-19 |
Nadia Baalbaki, Erik Duijvelaar, Medhat M. Said, Job Schippers, Pierre M. Bet, Jos Twisk, et al. (+8) Sarah Fritchley, Cristina Longo, Kazien Mahmoud, Anke H. Maitland- van der Zee, Harm Jan Bogaard, Eleonora L. Swart, Jurjan Aman, Imke H. Bartelink |
| 10 |
[GO] |
2022―Nov―30 |
The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells |
Mohammed A.A. Saleh, Makoto Hirasawa, Ming Sun, Berfin Gülave, Jeroen Elassaiss-Schaap, Elizabeth C.M. de Lange |
| 11 |
[GO] |
2021―Sep―17 |
Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors |
Suyash Pant, N.R. Jena |
| 12 |
[GO] |
2021―Mar―26 |
In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2) |
Sagar Barge, Dhananjay Jade, Gokul Gosavi, Narayan Chandra Talukdar, Jagat Borah |
| 13 |
[GO] |
2021―Feb―21 |
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach |
Yiming Zhang, Rory A Greer, Yuwei Song, Hrithik Praveen, Yuhua Song |
| 14 |
[GO] |
2021―Feb―02 |
Importance of Glutamine 189 flexibility in SARS-CoV-2 main protease: lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics |
Mohamed A. Said, Amgad Albohy, Mohamed A Abdelrahman, Hany S. Ibrahim |
| 15 |
[GO] |
2020―Oct―25 |
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial |
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, et al. (+7) Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu |
| 16 |
[GO] |
2020―Sep―30 |
Therapeutic Strategies for SARS-CoV-2 acting on ACE-2 |
A. Vitiello, F. Ferrara |
| 17 |
[GO] |
2020―Aug―20 |
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
Manisha Yadav, Swasti Dhagat, J. Satya Eswari |
| 18 |
[GO] |
2020―Jul―28 |
Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages |
Natesh Singh, Etienne Decroly, Abdel-Majid Khatib, Bruno O. Villoutreix |
| 19 |
[GO] |
2020―Jul―12 |
A Molecular Docking Study Repurposes FDA Approved Iron Oxide Nanoparticles to Treat and Control COVID-19 Infection |
Yasmin Abo-zeid, Nasser.S. Ismail, Gary.R. McLean, Nadia.M. Hamdy |
| 20 |
[GO] |
2020―May―23 |
Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics |
Sajjad Ahmad, Afifa Navid, Rabia Farid, Ghulam Abbas, Faisal Ahmad, Naila Zaman, et al. (+2) Nousheen Parvaiz, Syed Sikander Azam |
| 21 |
[GO] |
2020―May―14 |
High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 |
Rupal Ojha, Nidhi Gupta, Biswajit Naik, Satyendra Singh, Vijay Kumar Verma, Dhaneswar Prusty, Vijay Kumar Prajapati |
|
